Metropolis Healthcare’s Board has approved an interim dividend of INR 4 per share. The decision was made alongside the approval of the company’s unaudited standalone and consolidated financial results for Q2 2025 (July-September). Key financial figures show a profit before tax of ₹7,102.57 lakhs and a total comprehensive income of ₹5,488.59 lakhs.
Interim Dividend Declared
The Board of Directors has declared an interim dividend of INR 4 per equity share with a face value of INR 2. The record date for determining shareholders eligible for the dividend is November 11, 2025. The dividend will be dispatched or credited within 30 days of the declaration.
Q2 2025 Financial Highlights
The Board approved the unaudited standalone and consolidated financial results for the second quarter of the financial year. Key figures from the consolidated results include:
- Revenue from operations: ₹42,919.14 lakhs
- Total Income: ₹43,008.24 lakhs
- Profit before tax: ₹7,102.57 lakhs
- Profit for the period: ₹5,289.01 lakhs
- Total comprehensive income: ₹5,488.59 lakhs
- Earnings per share (basic): ₹10.17
Business Updates
Several business acquisitions were finalized in 2025, impacting the company’s structure. These include:
- Dapic Metropolis Healthcare Private Limited: Acquired in May 2025.
- Scientific Metropolis Pathology Private Limited: Acquired in June 2025, leading to the company ceasing to be a wholly-owned subsidiary.
- Dr. RS Patil’s Ambika Pathology Laboratory: Acquired in September 2025, expanding the company’s laboratory network in Maharashtra.
Source: BSE